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Abstract
Rationale:Antiphospholipid syndrome (APS) in pregnancymay trigger the life-threatening catastrophic antiphospholipid syndrome
(CAPS). Complement activation is implicated in the pathogenesis, and inhibition of complement factor C5 is suggested as an
additional treatment option.
Patient concerns, diagnosis and interventions: We present a pregnant patient treated with the C5-inhibitor eculizumab
due to high risk of developing devastating APS-related complications. The complement inhibitory effects of the treatment were
examined both in the patient and the premature infant.
Outcomes: Complement activity in the mother recovered considerably faster than anticipated; however, no new thrombosis or
CAPS developed during the last week of pregnancy or postpartum. Blood sampling from the umbilical vein and artery, and from the
infant after delivery showed low complement activity; however, only 0.3% of the eculizumab concentration detected in the mother,
consistent with low placental passage of eculizumab.
Lessons:The data underscore the importance of close monitoring of complement inhibition and individualizing dosage regimens in
pregnant patients receiving eculizumab. We document how traditional functional complement activity tests cannot assess the effect
of eculizumab in premature infants due to the very low levels of complement factors detected in this infant born in gestational week
33. Only trace amounts of eculizumab passed the placenta. In conclusion, complement C5 inhibition might be a safe candidate
treatment option for APS during pregnancy and delivery, and additionally, enables prolongation of pregnancy with important weeks.
Abbreviations: APS = antiphospholipid syndrome, CAPS = catastrophic antiphospholipid syndrome, E-C5 = eculizumab-C5,
EDTA = ethylenediaminetetraacetic acid, IgG = immunoglobulin G.
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1. Introduction in the presence of persistent antiphospholipid antibodies
(anticardiolipin antibodies, antibeta2 glycoprotein 1 antibodies,Antiphospholipid syndrome (APS) is characterized by arterial,
venous, or small-vessel thrombosis and/or pregnancy morbidityEditor: Rita Marchi.
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and lupus anticoagulant).[1] Although the pathogenesis is not
fully understood, the binding of antiphospholipid antibodies to
b2 beta2 glycoprotein 1 promotes endothelial cell activation
determined by upregulation of adhesion molecules, tissue factor,
and production and secretion of proinflammatory cytokines,
which enhance the risk of thrombosis formation.[2] Complement
appears to play a significant role in the pathophysiology based on
both in vitro and in vivo studies.[3–5] Catastrophic APS (CAPS),
although rare, is a devastating and life-threatening syndrome
featured by multiorgan thrombosis. Infection, surgery, pregnan-
cy, and puerperium are identified triggers of CAPS.[6,7] Current
treatment options in addition to anticoagulation are glucocorti-
coids, plasma exchange, or intravenous immunoglobulins;
however, case reports have reported that inhibition of comple-
ment may be lifesaving.[8–10]2. Case report
A 22-year-old primigravida was admitted to hospital in the 2nd
trimester with painful ulcerations of ischemic origin in her right
leg. Barely 14 years old, she developed her 1st episode of lower
limb arterial thrombosis which was treated with bypass grafting
and digital amputations. No arteriosclerosis or vasculitis was
detected and she was diagnosed with APS, fulfilling the Sydney
[1]
Figure 1. Complement activity and E-C5 complexes in a pregnant patient with APS and the newborn infant. (A) The patient received eculizumab 600mg day 0 and
7 and a caesarean section was performed on day 8. Effect of eculizumab on complement functional activity wasmeasured as a common readout (C5b-9 formation)
for the CP, LP, and AP, by ELISA in patient serum obtained before and repeatedly after the administration of eculizumab. E-C5 complexes were measured by ELISA
at day 0, 2, and 8 in the patient serum before and after administration of eculizumab. Complement activity was completely abolished by eculizumab 600mg,
however normalized within 7 days. The increased activity was revealed after 3 days following the 2nd dose. Consistently, E-C5 complexes showed an inverse
pattern with high levels following eculizumab administration. (B) The infant’s E-C5 complexes were measured by ELISA in infant serum (left column) and
subsequently after in vitro challenge with purified complement protein C5 (50mg/mL) (middle column) and eculizumab (100mg/mL) (right column). The increased E-
C5 complex formation following challenge with eculizumab, but not C5, is consistent with the presence of free C5 in infant serum and negligible levels of eculizumab.
AP=alternative pathway, APS=antiphospholipid syndrome, CAPS=catastrophic antiphospholipid syndrome, CP=classical pathway, E-C5=eculizumab-C5,
EDTA=ethylenediaminetetraacetic acid, ELISA=enzyme-linked immunosorbent assay, LP= lectin pathway.
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bodies: anticardiolipin immunoglobulin G (IgG) 205GPL-U/L
(ref<10GPL-U/L), antibeta 2 glycoprotein 1 IgG 125U/mL
(ref<10U/mL), and positive lupus anticoagulant 2.41 (ref<1.3
Silica Clotting time). Lifelong warfarin treatment was com-
menced. A recurrent episode of thrombosis was treated with
percutaneous transluminal angioplasty, and an episode of
microemboli resolved with intensified anticoagulant treatment.
In conjunction with pregnancy, warfarin was substituted with
low molecular weight heparin adjusted up to 10,000IU twice
daily (antifactor Xa levels of 0.9–1.1 IU/mL) and low dose aspirin
(75mg daily). Ischemia was treated conservatively with analgesia
in addition to anticoagulation therapy, and pregnancy was
monitored by regular ultrasounds following fetal growth and
placental function.
Based on her multiple previous arterial thromboses and
ongoing ischemia during pregnancy, the risk of developing CAPS
in relation to pregnancy, delivery, and puerperium was
considered significant. Ruffatti et al[11] published data suggesting
that addition of 2nd-line therapy increases live-birth rates in high
risk pregnant patients with APS, although no guidelines are
currently available on the ideal treatment strategy. Previous
experience with the efficacy of the complement C5 inhibitor
eculizumab in treatment of CAPS and described safety in
pregnancy[8,12,13] prompted the choice of eculizumab. Thus, 600
mg of eculizumabwas administered 8 days before delivery (day 0)
in addition to prophylactic antibiotics. Serum (prepared by
drawing whole blood into empty tubes, left for clotting 60
minutes followed by centrifugation 15minutes, 3500g, 4 °C) and
ethylenediaminetetraacetic acid (EDTA) plasma (prepared by
drawing blood into K2EDTA tubes, followed by immediate
centrifugation 15minutes, 3500g, 4 °C) samples were obtained
from the patient before and at several time points after
eculizumab administration and analyzed directly or stored at
70 °C. Complement activity in plasma (Total Complement
System Screen, WIESLAB, Malmo, Sweden) decreased to zero
after the 1st eculizumab infusion and remained low at day 2,
however had returned to normal levels already by day 7 (Fig. 1A).2
Eculizumab-C5 (E-C5) complexes in serum (enzyme immunoas-
say as described in ref[12]) increased from zero to 67 after the 1st
eculizumab dose (Fig. 1A). Interestingly, the patient reported
decreased ischemic pain following the 1st dose of eculizumab,
and opioid analgesia was successfully reduced.
A 2nd dose of eculizumab 600mg was infused on day 7, and a
caesarean section was performed the following day (day 8) in
gestational week 32+4, resulting in delivery of a healthy infant
(Apgar 8/9/9) with a normal weight (1875g) for gestational age.
Serum and EDTA plasma samples were obtained from the
umbilical cord artery and vein by careful needle puncture to avoid
contamination from mothers’ blood and Wharton jelly, directly
after cord clamping during caesarean section. In addition, EDTA-
plasma was obtained from the infant 2 hours after delivery.
Samples were analyzed directly or stored at 70 °C. The infant’s
total complement activity was<1%, however consistent with the
measured low complement protein concentrations (standard
routine immunochemical methods, Department of Clinical
Immunology and Transfusion Medicine, Lund, Sweden) as
expected at gestational week 32 (Table 1).[14] Umbilical and
infant E-C5 complexes were 0.3mg/mL. Concomitant patient E-
C5 complexes were 98mg/mL consistent with a 0.3% placental
passage of eculizumab (Table 1). To further support the findings
of low eculizumab passage, we added eculizumab (final
concentration of 100mg/mL) or purified C5 (50mg/mL),
respectively, to the infant serum in vitro and subsequently
analyzed for E-C5 complexes. Eculizumab, but not C5, increased
the E-C5 complex formation in infant serum substantially
(Fig. 1B), consistent with the presence of free C5 (Table 1) and
negligible amounts of eculizumab.
Close monitoring of the patient’s complement activity after the
2nd dose revealed increased activity already after 3 days and
again normal activity within 1 week (Fig. 1A). The patient did not
develop new thrombosis or CAPS during the last week of
pregnancy or postpartum. The intervention given (eculizumab)
was part of normal health care and thus ethical approval was
neither obliged nor sought. However, written consent was
obtained from the patient in order to publish the case report.
Table 1
Complement protein levels, complement activity, and eculizumab-C5 complexes in samples from a pregnant eculizumab-treated patient
with antiphospholipid syndrome before delivery and from the patient and newborn infant immediately after delivery.
Reference range (adult) Patient day 0
∗
Patient day 8† Infant day 8†
C1q, % 78–131 55 47 33
C4, g/L 0.1–0.5 0.20 0.18 0.06
C3, g/L 0.7–2.0 1.38 1.40 0.41
C5, % 72–171 159 272 43
C6, % 63–154 128 119 15
C7, % 64–154 112 129 47
C8, % 45–203 91 99 19
Classical pathway activity, % >40 100 3 0
Lectin pathway activity, % >10 100 11 0
Alternative pathway activity, % >10 28 1 0.5
Eculizumab-C5 complexes, mg/mL 0 98 0.3
∗
Day 0: day of the 1st dose of eculizumab (sample obtained before treatment).
† Day 8: day of delivery by caesarean section (day after the 2nd dose of eculizumab).
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A history of thrombosis and triple positive antiphospholipid
antibodies, as seen in the present patient, is associated with a
higher risk of maternal and fetal complications in pregnant
women with APS.[11,15] Our patient demonstrated multiple risk
factors and showed clinical signs of thrombosis despite intensive
anticoagulant treatment. Additionally, the risk of peri- and
postoperative hemorrhage due to intense anticoagulant treatment
was high, while on the other hand, surgery and cessation of
anticoagulant treatment would increase the risk of triggering
CAPS. Consequently, additional treatment was warranted.
Eculizumab has been suggested in several recent reports as a
2nd-line treatment option in APS and CAPS.[6,8,16] Hence, a short
term course of eculizumab was chosen before cesarean section to
reduce the risk of CAPS triggered by delivery and puerperium.
The ischemic symptoms declined following the 1st dose and no
adverse effects were seen.
Complement activity surprizingly increased to normal levels
within 7 days after both doses of eculizumab despite complete
inhibition of complement activity after each infusion. Others
have observed a similar requirement of an increased eculizumab
dosage regimen as pregnancy proceeds.[13] Eculizumab is
distributed mainly in the plasma volume and degraded by
lysosomal enzymes.[17] However, pregnancy-induced changes of
the normal physiology may influence the pharmacokinetics and
pharmacodynamics of eculizumab, underscoring the importance
of individual treatment monitoring.
Eculizumab is amonoclonal antibody based on an IgG subclass
2/4 hybrid. Data from pregnancies in patients with paroxysmal
nocturnal hemoglobinuria treated with eculizumab suggest that
the treatment is safe.[13] We examined both arterial and venous
blood samples from the umbilical cord, as well as a blood sample
from the infant 2 hours after delivery. All 3 samples showed
similar results, suggesting that virtually no eculizumab (approxi-
mately 0.3%) had passed the placenta. To our knowledge the
amount of eculizumab has previously not been examined in
preterm newborns at this stage of gestation. Collectively, these
data indicate that the IgG subclass 2/4 chimeric structure of
eculizumab largely prevents the molecule from passing the
placental barrier.
The observed complement activity of less than 1% in the
infant could have been misinterpreted as an eculizumab effect.
Eculizumab blocks cleavage of C5 and thus prevents assembly3
of the terminal C5b-9 complement complex detected in the
complement function enzyme-linked immunosorbent assay
(ELISA). However, a normal complement activity test requires
adequate levels of complement proteins to produce sufficient
amounts of TCC for assay detection. Premature infants have
low levels of most complement proteins,[14] as did the infant
in this report. The detection of merely trace levels of E-C5
complexes in the infant samples and the results from the in
vitro assay demonstrating that only the addition of eculizu-
mab, but not purified C5, could increase the E-C5 complex
formation in infant serum, indicate that the low complement
activity resulted from the low levels of most of the
complement proteins (eg, C4, C3, C5, C6, and C8), and
was not due to the presence of eculizumab. Consequently,
abnormal results in complement activity assays, such as in
premature infants, must be carefully interpreted to avoid
incorrect conclusions.4. Conclusion
In conclusion, these results add up to the increasing body of
literature stating that eculizumab treatment can be considered
safe in pregnancy as negligible amounts pass over the placental
barrier. Our data suggest complement inhibition as a treatment
option to safely prolong pregnancy and reduce the risk of CAPS
triggered by pregnancy, surgery, and puerperium without
affecting the infant. In addition, we stress the importance of
monitoring treatment effects of eculizumab using reliable
methods to ensure individual adequate complement inhibition.References
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